Basic Stats
| CIK | 1821586 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MoonLake Immunotherapeutics
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMU |
|
| August 5, 2025 |
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update •Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026 •Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 months •Ended the second quarter with $425. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (C |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 MoonLake Immunotherapeutics (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 98-1711963 (State or other jurisdiction of incorporation or or |
|
| May 12, 2025 |
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update •Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axia |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMM |
|
| May 12, 2025 |
Form of Restricted Stock Award. MOONLAKE IMMUNOTHERAPEUTICS 2022 EQUITY INCENTIVE PLAN GRANT NOTICE FOR RESTRICTED STOCK AWARD FOR GOOD AND VALUABLE CONSIDERATION, MoonLake Immunotherapeutics (the “Company”), hereby grants to the Participant named below the number of shares of Restricted Stock specified below (the “Award”) upon the terms and subject to the conditions set forth in this Grant Notice, the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (as amended from time to time, the “Plan”) and the Standard Terms and Conditions (the “Standard Terms and Conditions”) promulgated under such Plan and attached hereto as Exhibit A. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 12, 2025 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2025 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (C |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 22, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O |
|
| April 3, 2025 |
Exhibit 99.1 MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates ● Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operation |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (C |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2025 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| February 26, 2025 |
Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMUNOTH |
|
| February 26, 2025 |
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update •Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best |
|
| February 26, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the material provisions of the share capital of MoonLake Immunotherapeutics (“we,” “us,” “our” and the “Company”). As of December 31, 2024, our Class A ordinary share is the only class of our securities registered pursuant to Sectio |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| November 7, 2024 |
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update •Ended the third quarter with $493. |
|
| October 8, 2024 |
SC 13D/A 1 sc13da307422mltx10082024.htm AMENDMENT NO. 3 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares, $0.0001 p |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation |
|
| August 7, 2024 |
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 •Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis suppurativa (“HS”), with topline results anticipated as of mid-2025 •Secured positive feedback from both U. |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (C |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMU |
|
| June 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 10, 2024 |
Exhibit 99.1 MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis ● Builds upon the positive regulatory feedback received from FDA and EMA on Phase 3 VELA program for sonelokimab in hidradenitis suppurativa (HS), which has started recruitment ● Clarified path for PsA Phase 3 pro |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 MoonLake Immunotherapeutics (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 98-1711963 (State or other jurisdiction of incorporation or or |
|
| May 7, 2024 |
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update •Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025 •Reported significant improvements observed across all ke |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-396 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMM |
|
| May 7, 2024 |
May 7, 2024 Via EDGAR (filed as Correspondence) U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tara Harkins and Lynn Dicker Re: MoonLake Immunotherapeutics Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-39630 Dear Ms. Harkins and Ms. Dicker: This letter responds to the comment of t |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 24, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 11, 2024 |
Exhibit 99.2 W: moonlaketx.com | E: [email protected] © 2024 | Proprietary | MoonLake TX MoonLake Immunotherapeutics March 10 th 2024 R&D Day San Diego, during AAD Welcome to our R&D Day Agenda Sub - topics Topic Speaker Timing Date: March 10th, 2024 Time: 09.00 - 11:30 PST Location: Westin San Diego Bayview (Webcast also available) Logistics - Welcome & session details Introduction Matthias Bod |
|
| March 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (C |
|
| March 11, 2024 |
Exhibit 99.1 MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day ● Positive 24-week data from the ARGO trial of sonelokimab in PsA: o Significant improvements observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an ACR50 response at |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) 61559X104 (CUSIP Numbe |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMUNOTH |
|
| February 29, 2024 |
Subsidiaries of MoonLake Immunotherapeutics Exhibit 21.1 Subsidiaries of MoonLake Immunotherapeutics MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) MoonLake Immunotherapeutics Ltd, a private limited company incorporated in the United Kingdom MNLK Immunotherapeutics, Unipessoal Lda, a private limited company incorporated in Portugal |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 29, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| February 29, 2024 |
Incentive Compensation Clawback Policy INCENTIVE COMPENSATION CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of MoonLake Immunotherapeutics (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any such correction |
|
| February 29, 2024 |
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 •A successful year including the announcements of positive data from two Phase 2 trials of sonelokimab in hidradenitis suppurativa (HS), at 12 and 24 weeks, and active psoriatic arthritis (PsA), at 12 weeks, supporting a potential best-in-class profile across two key indications •Phase 3 preparation for sonelokimab in HS nearing completion, following positive feedback from both FDA and EMA •Year-end cash, cash equivalents and short-term marketable debt securities of $511. |
|
| February 29, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the material provisions of the share capital of MoonLake Immunotherapeutics (“we,” “us,” “our” and the “Company”). As of December 31, 2023, our Class A ordinary share is the only class of our securities registered pursuant to Sectio |
|
| February 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2024 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| February 26, 2024 |
Exhibit 99.1 MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) ● Clarified path for HS Phase 3 program with study design, patient population and endpoints agreed ● One dose of SLK (120mg) to be tested with a similar protocol as in Phase 2 ● Total Phase 3 popula |
|
| February 15, 2024 |
Exhibit 99.2 Power of Attorney Exhibit 99.2 POWER OF ATTORNEY E. Merck KG, Darmstadt, Germany (the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Mülllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact (each of such persons and their substitutes being refe |
|
| February 15, 2024 |
EX-99.1 2 tm246392d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of MoonLake Immunotherapeutics. This Joint Filing Agre |
|
| February 15, 2024 |
HLXA / Helix Acquisition Corp - Class A / Merck Healthcare KGaA - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* MoonLake Immunotherapeutics (Name of Issuer) Class A ordinary share, par value $0.0001 per share (Title of Class of Securities) G4444C102 (C |
|
| February 14, 2024 |
MLTX / MoonLake Immunotherapeutics / Chen Bihua - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) 61559X104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| February 14, 2024 |
MLTX / MoonLake Immunotherapeutics / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* MoonLake Immunotherapeutics (Name of Issuer) Class A ordinary share, par value $0.0001 per share (the “Shares”) (Title of Class of Securiti |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE |
|
| November 14, 2023 |
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update •Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa •Presented positive 12-week data from the global Phase 2 MIRA clinical trial for so |
|
| November 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| November 6, 2023 |
W: moonlaketx.com | E: [email protected]© 2023 | Proprietary | MoonLake TX MoonLake Immunotherapeutics R&D Day Webcast Presentation Document – Results ARGO trial November 6th 2023 © 2023 | Proprietary | MoonLake TXSource: Welcome to our R&D Day MoonLake Corporate 2 Date: November 6th, 2023 Time: 8am EDT Location: Nasdaq (Webcast) Sub-topicsTopic Lead Timing - Conclusions - Overall value of MLTX |
|
| November 6, 2023 |
Exhibit 99.1 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis •First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile •Primary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on soneloki |
|
| October 16, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) |
|
| October 16, 2023 |
Exhibit 99.1 MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) ● Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark week |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 98-1711963 (State or other jurisdiction of incorporation |
|
| September 11, 2023 |
MoonLake Immunotherapeutics Capital Markets Day Presentation dated September 11, 2023 Exhibit 99.1 |
|
| September 7, 2023 |
MOONLAKE IMMUNOTHERAPEUTICS Dorfstrasse 29 6300 Zug MOONLAKE IMMUNOTHERAPEUTICS Dorfstrasse 29 6300 Zug Switzerland VIA EDGAR September 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) ( |
|
| August 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MoonLake Immunotherapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Ordinary shares, $0. |
|
| August 31, 2023 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.1 MOONLAKE IMMUNOTHERAPEUTICS, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [l], 202[l] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif |
|
| August 31, 2023 |
As filed with the Securities and Exchange Commission August 31, 2023 As filed with the Securities and Exchange Commission August 31, 2023 Registration No. |
|
| August 31, 2023 |
Form of indenture of subordinated debt securities and related form of subordinated debt security. Exhibit 4.2 MOONLAKE IMMUNOTHERAPEUTICS, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [l], 202[l] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’ |
|
| August 31, 2023 |
Exhibit 1.2 MOONLAKE IMMUNOTHERAPEUTICS Class A Ordinary Shares (par value $0.0001 per share) SALES AGREEMENT August 31, 2023 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMU |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) ( |
|
| August 10, 2023 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| August 10, 2023 |
Exhibit 99.1 MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update ● Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS), suggesting that, as early as week 12, the Nanobody® sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly st |
|
| August 10, 2023 |
Share Participation Plan 1 Employee Share Participation Plan dated June 15, 2023 of MoonLake Immunotherapeutics AG, Zug, Switzerland Share Participation Plan 2 TABLE OF CONTENTS 1. |
|
| August 10, 2023 |
Employee Stock Option Plan dated June 15, 2023 of MoonLake Immunotherapeutics AG, Zug, Switzerland Employee Stock Option Plan 2 TABLE OF CONTENTS 1 General Terms 3 2 Interpretations 3 3 Definitions 3 4 Administration of the Participation Plan 8 5 Size and Funding of the Participation Plan 9 6 Right to Participate 9 7 Granting of Options 10 8 Vesting Provisions 11 9 Exercise and Settlement of Optio |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) 61559X104 (CUSIP Numbe |
|
| June 29, 2023 |
MoonLake Immunotherapeutics Underwriting Agreement Exhibit 1.1 MOONLAKE IMMUNOTHERAPEUTICS (a Cayman Islands exempted company) 8,000,000 Ordinary Shares UNDERWRITING AGREEMENT June 27, 2023 SVB Securities LLC and Guggenheim Securities LLC as Representatives of the several Underwriters c/o SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 c/o Guggenheim Securities LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: MoonLak |
|
| June 29, 2023 |
8,000,000 Class A Ordinary Shares MOONLAKE IMMUNOTHERAPEUTICS Filed Pursuant to Rule 424(b)(5) Registration No. 333-271546 PROSPECTUS SUPPLEMENT (To prospectus dated May 9, 2023) 8,000,000 Class A Ordinary Shares MOONLAKE IMMUNOTHERAPEUTICS We are offering 8,000,000 Class A Ordinary Shares, par value $0.0001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each Class A Ordinary Share is $50.00. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 27, 2023 |
PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED MAY 11, 2023 Filed Pursuant to Rule 424(b)(3) Registration No. 333-271546 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED MAY 11, 2023 This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 11, 2023 (the “Prospectus”), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $200,000,000 (the “Maximum Offering Amount”) of our Class A ordinary shares, pa |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 26, 2023 |
Subject to Completion Preliminary Prospectus Supplement dated June 26, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-271546 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted. Subject to C |
|
| June 26, 2023 |
Exhibit 99.1 MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa •First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint •Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS |
|
| June 26, 2023 |
exhibit992-8xk W: moonlaketx.com | E: [email protected]© 2023 | Proprietary | MoonLake TX MoonLake Immunotherapeutics R&D Day Webcast Presentation Document – Results MIRA trial June 26th 2023 © 2023 | Proprietary | MoonLake TXSource: Welcome to our R&D Day MoonLake Corporate 2 Cowen conference (March 6-8) AAD (March 18) Capital Markets Day (April 19) Kempen conference (April 25-26) HCW & Guggenh |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 MoonLake Immunotherapeutics (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 98-1711963 (State or other jurisdiction of incorporation or or |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 98-1711963 (State or other jurisdiction of incorporation) (Com |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMM |
|
| May 11, 2023 |
Sales Agreement, dated May 11, 2023, between MoonLake Immunotherapeutics and SVB Securities LLC Exhibit 10.1 MOONLAKE IMMUNOTHERAPEUTICS Class A Ordinary Shares (par value $0.0001 per share) SALES AGREEMENT May 11, 2023 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follow |
|
| May 11, 2023 |
MOONLAKE IMMUNOTHERAPEUTICS Up to $200,000,000 Class A Ordinary Shares 424B5 1 moonlake424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-271546 PROSPECTUS SUPPLEMENT (To prospectus dated May 9, 2023) MOONLAKE IMMUNOTHERAPEUTICS Up to $200,000,000 Class A Ordinary Shares We have entered into a sales agreement, dated May 11, 2023 (the “Sales Agreement”), with SVB Securities LLC (“SVB Securities”), relating to our Class A ordinary shares, par value $ |
|
| May 5, 2023 |
MOONLAKE IMMUNOTHERAPEUTICS Dorfstrasse 29 6300 Zug MOONLAKE IMMUNOTHERAPEUTICS Dorfstrasse 29 6300 Zug Switzerland VIA EDGAR May 5, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 1, 2023 |
Form of indenture of subordinated debt securities and related form of subordinated debt security. Exhibit 4.2 MOONLAKE IMMUNOTHERAPEUTICS, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [l], 202[l] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’ |
|
| May 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MoonLake Immunotherapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Ordinary shares, $0. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission May 1, 2023 As filed with the Securities and Exchange Commission May 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 001-39630 (Comm |
|
| May 1, 2023 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.1 MOONLAKE IMMUNOTHERAPEUTICS, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [l], 202[l] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 98-1711963 (State or other jurisdiction of incorporation) (C |
|
| April 19, 2023 |
MoonLake Immunotherapeutics Capital Markets Day Presentation dated April 19, 2023 Exhibit 99.1 |
|
| March 31, 2023 |
KY:MLTX / MoonLake Immunotherapeutics / Chen Bihua Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) 61559X104 (CUSIP Number) December 31, 2022† (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| March 28, 2023 |
MOONLAKE IMMUNOTHERAPEUTICS 40,187,019 Class A Ordinary Shares Offered by the Selling Shareholders PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-262643 MOONLAKE IMMUNOTHERAPEUTICS 40,187,019 Class A Ordinary Shares Offered by the Selling Shareholders This prospectus relates to the resale from time to time by the selling shareholders named in this prospectus or their permitted transferees (collectively, the “Selling Shareholders”) of up to 40,187,019 Class A ordinary shares of |
|
| March 20, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the material provisions of the capital stock of MoonLake Immunotherapeutics (“we,” “us,” “our” and the “Company”). As of December 31, 2022, our Class A ordinary share is the only class of our securities registered pursuant to Sectio |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 001-39630 98-1711963 (State or Other Jurisdiction of Incorporation) (C |
|
| March 20, 2023 |
As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No. |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMUNOTH |
|
| March 20, 2023 |
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update •Strong financial position: year-end cash, cash equivalents and short-term marketable debt securities of $72. |
|
| March 20, 2023 |
EMPLOYEE FORM Exhibit 10.25 MOONLAKE IMMUNOTHERAPEUTICS 2022 EQUITY INCENTIVE PLAN GRANT NOTICE FOR NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, MoonLake Immunotherapeutics (the “Company”), hereby grants to Participant named below the Nonqualified Stock Option (the “Option”) to purchase any part or all of the number of Common Shares that are covered by this Option at the Exercis |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I |
|
| February 14, 2023 |
KY61559X1045 / MOONLAKE IMMUNOTHERAPEUTICS / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm234574-24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share |
|
| February 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Moonlake Immunotherapeutics (f/k/a Helix Acquisition Corp.) (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 61559X104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check |
|
| January 27, 2023 |
HLXA / Helix Acquisition Corp. / Merck Healthcare KGaA - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* MoonLake Immunotherapeutics (Name of Issuer) Class A ordinary share, par value $0.0001 per share (Title of Class of Securities) G4444C102 (C |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE |
|
| November 14, 2022 |
MOONLAKE IMMUNOTHERAPEUTICS 49,281,756 Class A Ordinary Shares Offered by the Selling Shareholders Prospectus Supplement No. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 2, 2022) Registration No. 333-262643 MOONLAKE IMMUNOTHERAPEUTICS 49,281,756 Class A Ordinary Shares Offered by the Selling Shareholders This prospectus supplement no. 2 is being filed to update and supplement information contained in the prospectus dated August 2, 2022 (the ?Prospectus?) related to the offer a |
|
| September 30, 2022 |
As filed with the Securities and Exchange Commission on September 30, 2022 As filed with the Securities and Exchange Commission on September 30, 2022 Registration No. |
|
| September 30, 2022 |
Exhibit 107.1 Form S-8 (Form Type) MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Ordinary Share, $0.0001 par value per s |
|
| September 30, 2022 |
Exhibit 10.7 Employee Share Participation Plan dated June 22, 2022 of MoonLake Immunotherapeutics AG, Zug, Switzerland Table of Contents 1. General Terms 3 2. Interpretations 3 3. Definitions 3 4. Administration of the Participation Plan 8 5. Size and Funding of the Participation Plan 8 6. Right to Participate 8 7. Grant and acquisition of Shares 9 8. Conditions Precedent regarding the Transfer of |
|
| September 30, 2022 |
Exhibit 10.4 Employee Stock Option Plan dated June 22, 2022 of MoonLake Immunotherapeutics AG, Zug, Switzerland Table of Contents 1 General Terms 3 2 Interpretations 3 3 Definitions 3 4 Administration of the Participation Plan 8 5 Size and Funding of the Participation Plan 9 6 Right to Participate 9 7 Granting of Options 10 8 Vesting Provisions 11 9 Exercise and Settlement of Options 13 10 Termina |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMU |
|
| August 12, 2022 |
MOONLAKE IMMUNOTHERAPEUTICS 49,281,756 Class A Ordinary Shares Offered by the Selling Shareholders Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 2, 2022) Registration No. 333-262643 MOONLAKE IMMUNOTHERAPEUTICS 49,281,756 Class A Ordinary Shares Offered by the Selling Shareholders This prospectus supplement no. 1 is being filed to update and supplement information contained in the prospectus dated August 2, 2022 (the ?Prospectus?) related to the offer a |
|
| August 3, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of MoonLake Immunotherapeutics. This Joint Filing Agreement may be executed in counterparts and ea |
|
| August 3, 2022 |
Exhibit 99.2 POWER OF ATTORNEY E. Merck KG, Darmstadt, Germany (the ?Company?), hereby makes, constitutes and appoints each of Dr. Matthias M?lllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution, the Company?s true and lawful attorney-in-fact (each of such persons and their substitutes being refe |
|
| August 3, 2022 |
HLXA / Helix Acquisition Corp. / Merck Healthcare KGaA - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* MoonLake Immunotherapeutics (Name of Issuer) Class A ordinary share, par value $0.0001 per share (Title of Class of Securities) G4444C102 (CU |
|
| August 2, 2022 |
MOONLAKE IMMUNOTHERAPEUTICS 49,281,756 Class A Ordinary Shares Offered by the Selling Shareholders PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-262643 MOONLAKE IMMUNOTHERAPEUTICS 49,281,756 Class A Ordinary Shares Offered by the Selling Shareholders This prospectus relates to the resale from time to time by the selling shareholders named in this prospectus or their permitted transferees (collectively, the “Selling Shareholders”) of up to 49,281,756 Class A ordinary shares of |
|
| July 29, 2022 |
MOONLAKE IMMUNOTHERAPEUTICS Dorfstrasse 29 6300 Zug, Switzerland MOONLAKE IMMUNOTHERAPEUTICS Dorfstrasse 29 6300 Zug, Switzerland VIA EDGAR July 29, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| July 26, 2022 |
As filed with the Securities and Exchange Commission on July 26, 2022 As filed with the Securities and Exchange Commission on July 26, 2022 Registration No. |
|
| July 26, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) MoonLake Immunotherapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid ? ? ? ? ? ? ? ? ? ? ? ? Fees Previously Paid Equity Class A ordinary shares, par value $0. |
|
| July 26, 2022 |
July 26, 2022 CONFIDENTIAL SUBMISSION VIA EDGAR AND HAND DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky and Laura Crotty Re: MoonLake Immunotherapeutics Amendment No. 4 to Registration Statement on Form S-1 Filed July 15, 2022 File No. 333-262643 Ladies and Gentlemen: On behalf o |
|
| July 15, 2022 |
July 15, 2022 CONFIDENTIAL SUBMISSION VIA EDGAR AND HAND DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart and Laura Crotty Re: MoonLake Immunotherapeutics Amendment No. 3 to Registration Statement on Form S-1 Filed May 2, 2022 File No. 333-262643 Ladies and Gentlemen: On behalf of |
|
| July 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) MoonLake Immunotherapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid ? ? ? ? ? ? ? ? ? ? ? ? Fees Previously Paid Equity Class A ordinary shares, par value $0. |
|
| July 15, 2022 |
As filed with the Securities and Exchange Commission on July 15, 2022 As filed with the Securities and Exchange Commission on July 15, 2022 Registration No. |
|
| June 17, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2022 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I. |
|
| June 17, 2022 |
Exhibit 16.1 June 17, 2022 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read Moonlake Immunotherapeutic?s statements (formerly known as Helix Acquisition Corp.) included under Item 4.01 of its Form 8-K dated June 17, 2022. We agree with the statements concerning our Firm under Item 4.01, in which we were inf |
|
| June 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2022 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I.R |
|
| June 7, 2022 |
MoonLake Immunotherapeutics. Capital Markets Day Presentation dated June 7, 2022 Exhibit 99.1 |
|
| May 16, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2022 (April 5, 2022) MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdic |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMM |
|
| May 16, 2022 |
MOONLAKE MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MOONLAKE MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with MoonLake?s unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2022, included elsewhere in this current report on Form 8-K filing. |
|
| May 16, 2022 |
MoonLake Immunotherapeutics AG Unaudited Condensed Consolidated Financial Statements March 31, 2022 Exhibit 99.1 May 13, 2022 MoonLake Immunotherapeutics AG Unaudited Condensed Consolidated Financial Statements March 31, 2022 Content: Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 2 Condensed Consolidated Statement of Operations and Comprehensive Loss for the Three Months Ended March 31, 2022 3 Condensed Consolidated Statement of Changes in Shareholders? Deficit |
|
| May 16, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K/A (the ?Form 8-K/A?) and, if not defined in the Form 8-K/A, the revised definitive proxy statement filed with the Securities and Exchange Commission (the ?SEC?) on March 4, 2022 (the ?Proxy Stat |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) MoonLake Immunotherapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Class A ordinary shares, par value $0. |
|
| May 2, 2022 |
As filed with the Securities and Exchange Commission on May 2, 2022 As filed with the Securities and Exchange Commission on May 2, 2022 Registration No. |
|
| May 2, 2022 |
Exhibit 10.8 DATED [] (1) Helix Acquisition Corp. (2) [] SUBSCRIPTION AGREEMENT Table of Contents Clause Page 1. subscription and class c shares 1 2. Whole Agreement 2 3. ASSIGNMENT 2 4. Counterparts 2 5. General 2 6. governing law 2 7. Excluding Third party rights 2 i THIS AGREEMENT is made on [] BETWEEN (1) Helix Acquisition Corp. (the ?Company?), a Cayman Islands exempted company of Maples Corp |
|
| May 2, 2022 |
Exhibit 10.12 Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) unde |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 MoonLake Immunotherapeutics (Name of Issuer) Class A Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) 61559X104 (CUSIP Number |
|
| April 18, 2022 |
Exhibit 99.7 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated April 18, 2022 (including amendments thereto) with respect to the Class A Ordinary Shares, $0.0001 par value per share, of MoonLake Immunotherapeutics. Thi |
|
| April 11, 2022 |
Exhibit 10.33 MOONLAKE IMMUNOTHERAPEUTICS 2022 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT RECITALS A. The Company maintains the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (as the same may be amended, the ?Plan?) for the purpose of providing incentives to attract, retain and motivate Eligible Persons. B. This Stock Option Agreement (this ?Agreement?) is executed pursuant to, and is in |
|
| April 11, 2022 |
Exhibit 99.1 MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, will be listed on Nasdaq under the ticker ?MLTX? ZUG, Switzerland and Boston, U.S., April 5, 2022 ? MoonLake Immunotherapeutics AG, a clinical-stage biopharm |
|
| April 11, 2022 |
Exhibit 10.8 MOONLAKE IMMUNOTHERAPEUTICS 2022 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the ?Plan?) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance- |
|
| April 11, 2022 |
Exhibit 10.2 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Execution Version RESTATED AND AMENDED SHAREHOLDERS? AGREEMENT of 5 April 2022 between 1. Helix Acquisition Corp. c/o Cormorant Asset Management LLP, 200 Clarendon Street, 52nd Floor Boston, MA 02116, U |
|
| April 11, 2022 |
Exhibit 3.1 THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF MOONLAKE IMMUNOTHERAPEUTICS (ADOPTED BY SPECIAL RESOLUTION DATED 31 MARCH 2022 AND EFFECTIVE 5 APRIL, 2022) THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATIO |
|
| April 11, 2022 |
Exhibit 10.5 Execution Version AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of April 5, 2022, is made and entered into by and among: (i) MoonLake Immunotherapeutics (formerly known as Helix Acquisition Corp.), a Cayman Islands exempted company (the ?Company?); (ii) Helix Holdings LLC, a Cayman Islands limite |
|
| April 11, 2022 |
Code of Business Conduct and Ethics. Exhibit 14.1 Code of Business Conduct and Ethics (dated April 6, 2022) I. INTRODUCTION This Code of Business Conduct and Ethics (this ?Code?) provides a general statement of the expectations of MoonLake Immunotherapeutics (the ?Company?) regarding the ethical standards to which each director, officer and employee should adhere while acting on behalf of the Company. You are expected to read and bec |
|
| April 11, 2022 |
Exhibit 10.7 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into on April , 2022 by and between Helix Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and the subscriber party set forth on the signature page hereto (the ?Subscriber?). WHEREAS, on October 4, 2022, the Company entered into a certain investment agreement (the ?Invest |
|
| April 11, 2022 |
Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K (the ?Form 8-K?) and, if not defined in the Form 8-K, the revised definitive proxy statement filed with the Securities and Exchange Commission (the ?SEC?) on March 4, 2022 (the ?Proxy Statement? |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2022 MOONLAKE IMMUNOTHERAPEUTICS (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I. |
|
| April 11, 2022 |
Exhibit 21.1 Subsidiaries of MoonLake Immunotherapeutics MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) MoonLake Immunotherapeutics Ltd, a private limited company incorporated in the United Kingdom |
|
| March 31, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I.R.S |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2022 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I.R.S |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2022 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I.R.S |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 24, 2022 |
Exhibit 10.1 PROMISSORY NOTE $ 150,000.00 As of March 21, 2022 Helix Acquisition Corp. (?Maker?) promises to pay to the order of Cormorant Asset Management LP or its successors or assigns (?Payee?) the principal sum of One Hundred Fifty Thousand Dollars and No Cents ($150,000.00) in lawful money of the United States of America, on the terms and conditions described below. 1. Principal. The princip |
|
| March 24, 2022 |
Exhibit 10.1 PROMISSORY NOTE $ 150,000.00 As of March 21, 2022 Helix Acquisition Corp. (?Maker?) promises to pay to the order of Cormorant Asset Management LP or its successors or assigns (?Payee?) the principal sum of One Hundred Fifty Thousand Dollars and No Cents ($150,000.00) in lawful money of the United States of America, on the terms and conditions described below. 1. Principal. The princip |
|
| March 14, 2022 |
Exhibit 10.10 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. April 29, 2021 Merck Healthcare KGaA Frankfurter Stra?e 250 64293 Darmstadt Germany Attention: Head of Alliance Management Merck Healthcare KGaA Frankfurter Stra?e 250 64293 Darmstadt Germany Attention |
|
| March 14, 2022 |
Exhibit 10.9 Execution Copy Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item |
|
| March 14, 2022 |
Exhibit 10.12 Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) unde |
|
| March 14, 2022 |
As filed with the Securities and Exchange Commission on March 14, 2022 As filed with the Securities and Exchange Commission on March 14, 2022 Registration No. |
|
| March 14, 2022 |
Exhibit 10.11 Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) unde |
|
| March 14, 2022 |
Exhibit 10.13 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. ASSIGNMENT This ASSIGNMENT AGREEMENT (the ?Assignment?) is entered into as of 1 July 2021, (?Assignment Effective Date?) by and among Merck Healthcare KGaA, Frankfurter StraBe 250, 64293 Darmstadt, Ger |
|
| March 8, 2022 |
Exhibit 10.30 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Amendment to the Loan Agreement dated as of October 15, 2021, as amended of February 15, 2022 between 1. Biotechnology Value Fund, L.P. 44 Montgomery Street, 40th Floor San Francisco, CA 94104, USA [** |
|
| March 8, 2022 |
Exhibit 10.25 Execution Version Employee Stock Option Plan dated 23 July 2021 of MoonLake Immunotherapeutics AG, Zug, Switzerland Employee Stock Option Plan Table of Contents 1 General Terms 3 2 Interpretations 3 3 Definitions 3 4 Administration of the Participation Plan 6 5 Size and Funding of the Participation Plan 6 6 Right to Participate 6 7 Granting of Options 7 8 Vesting Provisions 8 9 Exerc |
|
| March 8, 2022 |
Exhibit 10.26 Employee Share Participation Plan dated December 14, 2021 of MoonLake Immunotherapeutics AG, Zug, Switzerland Table of Contents 1. General Terms 3 2. Interpretations 3 3. Definitions 3 4. Administration of the Participation Plan 7 5. Size and Funding of the Participation Plan 8 6. Right to Participate 8 7. Grant and acquisition of Shares 9 8. Conditions Precedent regarding the Transf |
|
| March 8, 2022 |
Exhibit 10.29 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Amendment to the Loan Agreement dated as of October 15, 2021 of January 18, 2022 between 1. Biotechnology Value Fund, L.P. 44 Montgomery Street, 40th Floor San Francisco, CA 94104, USA [***] (hereinaft |
|
| March 8, 2022 |
Exhibit 10.24 Execution Version Employee Share Participation Plan dated 23 July 2021 of MoonLake Immunotherapeutics AG, Zug, Switzerland Table of Contents 1. General Terms 3 2. Interpretations 3 3. Definitions 3 4. Administration of the Participation Plan 7 5. Size and Funding of the Participation Plan 8 6. Right to Participate 8 7. Grant and acquisition of Shares 9 8. Conditions Precedent regardi |
|
| March 8, 2022 |
EX-10.21 10 fs12022a1ex10-21helixacqu.htm AMENDMENT TO EMPLOYMENT AGREEMENT, DATED SEPTEMBER 9, 2021, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG AND JONKHEER ARNOUT MICHIEL PLOOS VAN AMSTEL Exhibit 10.21 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Amendmen |
|
| March 8, 2022 |
EX-10.14 3 fs12022a1ex10-14helixacqu.htm EMPLOYMENT AGREEMENT, DATED APRIL 30, 2021, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG AND DR. JORGE SANTOS DA SILVA Exhibit 10.14 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Employment Agreement dated 30 April 2021 |
|
| March 8, 2022 |
Exhibit 10.15 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Amendment to Employment Agreement Between and MoonLake Immunotherapeutics AG Jorge Santos da Silva Unterm?li 7 / Postfach 7444 [***] 6302 Zug, Switzerland (?Employer?) (?Employee?) (together hereinafte |
|
| March 8, 2022 |
Exhibit 10.17 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Amendment to Employment Agreement Between and MoonLake Immunotherapeutics AG Prof. Dr. Kristian Reich Unterm?li 7 / Postfach 7444 [***] 6302 Zug, Switzerland (?Employer?) (?Employee?) (together hereina |
|
| March 8, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Helix Acquisition Corp. |
|
| March 8, 2022 |
EX-10.16 5 fs12022a1ex10-16helixacqu.htm EMPLOYMENT AGREEMENT, DATED APRIL 30, 2021, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG AND PROF. DR. KRISTIAN REICH Exhibit 10.16 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Employment Agreement dated 30 April 2021 |
|
| March 8, 2022 |
Exhibit 10.18 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Employment Agreement from 10.05.2021 between 1. MoonLake Immunotherapeutics AG c/o KD Zug-Treuhand AG Unterm?li 7 CH - 6302 Zug (hereinafter ?Employer? or ?Party?) and 2. Matthias Bodenstedt [***] (her |
|
| March 8, 2022 |
Exhibit 10.20 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Employment Agreement dated 30 April between 1. MoonLake Immunotherapeutics AG c/o KD Zug-Treuhand AG Unterm?li 7 6302 Zug (hereinafter ?Employer? or ?Party?) and 2. Jonkheer Arnout Michiel Ploos van Am |
|
| March 8, 2022 |
Exhibit 10.32 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) is made as of [], 2022, by and between MOONLAKE IMMUNOTHERAPEUTICS, a Cayman Islands exempted company (the ?Company?), and [] (?Indemnitee?). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided wit |
|
| March 8, 2022 |
Exhibit 10.23 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Execution Version BOARD MEMBER AGREEMENT Dated September 25, 2021 between 1. MoonLake Immunotherapeutics AG c/o KD Zug-Treuhand AG, Unterm?li 7, 6302 Zug, Switzerland (the ?Company?) and 2. Simon Sturg |
|
| March 8, 2022 |
As filed with the Securities and Exchange Commission on March 8, 2022 As filed with the Securities and Exchange Commission on March 8, 2022 Registration No. |
|
| March 8, 2022 |
Exhibit 10.28 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Loan Agreement of October 15, 2021 between 1. Biotechnology Value Fund, L.P. 44 Montgomery Street, 40th Floor San Francisco, CA 94104, USA [***] (hereinafter ?Lender 1?) 2. Biotechnology Value Fund II, |
|
| March 8, 2022 |
Exhibit 10.27 Employee Stock Option Plan dated December 14, 2021 of MoonLake Immunotherapeutics AG, Zug, Switzerland Table of Contents 1 General Terms 3 2 Interpretations 3 3 Definitions 3 4 Administration of the Participation Plan 8 5 Size and Funding of the Participation Plan 9 6 Right to Participate 9 7 Granting of Options 10 8 Vesting Provisions 11 9 Exercise and Settlement of Options 12 10 Te |
|
| March 8, 2022 |
Exhibit 10.22 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Execution Version Termination Agreement dated 13 December 2021 between MoonLake Immunotherapeutics Ltd Dorfstrasse 29 6300 Zug (?Employer?) and Jonkheer Arnout Michiel Ploos van Amstel [***] (?Employee |
|
| March 8, 2022 |
Exhibit 10.19 Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Amendment to Employment Agreement between 1. MoonLake Immunotherapeutics AG Unterm?li 7 / Postfach 7444 6302 Zug Switzerland (?Employer?) and 2. Matthias Bodenstedt [***] (?Employee?) (together hereina |
|
| March 4, 2022 |
DEFR14A 1 defr14a0222helixacqcorp.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: |
|
| February 25, 2022 |
Exhibit 10.1 Convertible Loan Agreement of February 20, 2022 between 1. Cormorant Private Healthcare Fund IV. L.P. 200 Clarendon St., 52nd Floor Boston, MA 02116, USA [email protected] (hereinafter ?Lender ?) and 2. MoonLake Immunotherapeutics AG Dorfstrasse 29 6300 Zug, Switzerland [email protected] and [email protected] (hereinafter the ?Borrower?) and 3. Biotechnolo |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2022 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I. |
|
| February 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2022 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I. |
|
| February 25, 2022 |
Exhibit 10.1 Convertible Loan Agreement of February 20, 2022 between 1. Cormorant Private Healthcare Fund IV. L.P. 200 Clarendon St., 52nd Floor Boston, MA 02116, USA [email protected] (hereinafter ?Lender ?) and 2. MoonLake Immunotherapeutics AG Dorfstrasse 29 6300 Zug, Switzerland [email protected] and [email protected] (hereinafter the ?Borrower?) and 3. Biotechnolo |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39630 HELIX ACQUISITION CORP. (E |
|
| February 17, 2022 |
Exhibit 4.5 DESCRIPTION OF SECURITIES The following description of our Class A ordinary shares and Class B ordinary shares is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated memorandum and articles of association, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this E |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission |
|
| February 14, 2022 |
HLXA / Helix Acquisition Corp. / CITADEL ADVISORS LLC - HELIX ACQUISITION CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* Helix Acquisition Corp (Name of Issuer) Class A ordinary share, $0.0001 par value per share (the ?Shares?) (Title of Class of Securities) G |
|
| February 11, 2022 |
As filed with the Securities and Exchange Commission on February 10, 2022 As filed with the Securities and Exchange Commission on February 10, 2022 Registration No. |
|
| February 11, 2022 |
PRER14A 1 prer14a4helixacq.htm PRELIMINARY REVISED PROXY MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 4) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the app |
|
| February 11, 2022 |
February 11, 2022 United States Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Helix Acquisition Corp. |
|
| February 11, 2022 |
Proposed Memorandum and Articles of Association of MoonLake Immunotherapeutics. Exhibit 3.2 THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF MOONLAKE IMMUNOTHERAPEUTICS (ADOPTED BY SPECIAL RESOLUTION DATED [DATE], 2022) THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF MOONLAKE IMMUNOTHERAPEUT |
|
| February 11, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Helix Acquisition Corp. |
|
| February 3, 2022 |
February 3, 2022 United States Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Helix Acquisition Corp. |
|
| February 3, 2022 |
PRER14A 1 prer14ahelixacquisition.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 3) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 2) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use |
|
| January 20, 2022 |
January 20, 2022 United States Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Helix Acquisition Corp. |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use |
|
| December 15, 2021 |
December 15, 2021 United States Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Helix Acquisition Corp. |
|
| December 14, 2021 |
CORRESP 1 filename1.htm December 14, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Sasha Parikh and Kevin Vaughn Helix Acquisition Corp. Form 10-K for the Year Ended December 31, 2020 Filed March 31, 2021 Form 10-Q for the Nine Months Ended September 30, 2021 Filed November 12, 2021 File No. 001-39630 Dea |
|
| December 14, 2021 |
Exhibit 4.5 DESCRIPTION OF SECURITIES The following description of our Class A ordinary shares and Class B ordinary shares is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated memorandum and articles of association, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this E |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39630 HELIX |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 HELIX ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2021 |
HLXA / Helix Acquisition Corp. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HELIX ACQUISITION CORP. (Name of Issuer) Class A Ordinary Share, par value $0.0001 per share (Title of Class of Securities) G4444C102 (CUSIP Number) November 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 HELIX AC |
|
| October 29, 2021 |
PREM14A 1 prem14ahelixacq.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy State |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| October 4, 2021 |
Exhibit 99.1 MoonLake ImmunotheraPeutics AG and Helix Acquisition Corp. Announce BUSINESS COMBINATION Agreement to Create PUBLICLY LISTED BIOTECHNOLOGY COMPANY ADVANCing tri-specific nanobody? sonelokimab - Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp.?s trust account and a private investment in public entity (PIPE) financing - Leading in |
|
| October 4, 2021 |
Investor Presentation, dated October 2021. Exhibit 99.2 1 ? 2021 | Confidential and Proprietary MoonLake Immunotherapeutics AG Proposed deal with Helix Acquisition Corp. STRICTLY CONFIDENTIAL September 2021 www.moonlaketx.com 2 Disclaimer (1/2) ? 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG Important Information for Investors This confidential presentation (?Presentation?) is for informational purposes only and is b |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2021 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I.R. |
|
| October 4, 2021 |
Form of Subscription Agreement. Exhibit 10.3 FORM OF SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into on October 4, 2021 by and between Helix Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and [each of] the subscriber part[y][ies] set forth on the signature page hereto ([each a/the] ?Subscriber?). WHEREAS, substantially concurrently with the execution of th |
|
| October 4, 2021 |
Exhibit 10.2 FORM OF RESTATED AND AMENDED SHAREHOLDERS? AGREEMENT of [date] between 1. Helix Acquisition Corp. c/o Cormorant Asset Management LLP, 200 Clarendon Street, 52nd Floor Boston, MA 02116, United States (hereinafter ?Helix?) and 2. Biotechnology Value Fund, L.P. 44 Montgomery Street, 40th Floor, San Francisco, CA 94104, United States (hereinafter ?Series A Investor 1?) 3. Biotechnology Va |
|
| October 4, 2021 |
Exhibit 10.1 Investment Agreement Dated October 4, 2021 by and among 1. Investor 1.1 Helix Acquisition Corp., c/o Cormorant Asset Management LLP, 200 Clarendon St., 52nd Floor, Boston, MA 02116 (?Investor?) 2. Founders 2.1 Jonkheer Arnout Michiel Ploos van Amstel (?Founder 1?) 2.2 Dr. Jorge Santos da Silva (?Founder 2?) 2.3 JeruCon Beratungsgesellschaft mbH, Alte Rabenstrasse 10a, 20148 Hamburg, G |
|
| October 4, 2021 |
Exhibit 10.3 FORM OF SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into on October 4, 2021 by and between Helix Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and [each of] the subscriber part[y][ies] set forth on the signature page hereto ([each a/the] ?Subscriber?). WHEREAS, substantially concurrently with the execution of th |
|
| October 4, 2021 |
Exhibit 99.3 [Slide 1] Jorge Santos da Silva: Thank you for joining our call today. In this call, we'll be discussing information contained in our press release just issued. Before we discuss what we believe is a very exciting announcement and a significant milestone for both MoonLake and Helix, we would like to make some important disclaimers. And I will ask our CFO to do those. [Slide 2] Matthia |
|
| October 4, 2021 |
Exhibit 10.1 Investment Agreement Dated October 4, 2021 by and among 1. Investor 1.1 Helix Acquisition Corp., c/o Cormorant Asset Management LLP, 200 Clarendon St., 52nd Floor, Boston, MA 02116 (?Investor?) 2. Founders 2.1 Jonkheer Arnout Michiel Ploos van Amstel (?Founder 1?) 2.2 Dr. Jorge Santos da Silva (?Founder 2?) 2.3 JeruCon Beratungsgesellschaft mbH, Alte Rabenstrasse 10a, 20148 Hamburg, G |
|
| October 4, 2021 |
Exhibit 99.3 [Slide 1] Jorge Santos da Silva: Thank you for joining our call today. In this call, we'll be discussing information contained in our press release just issued. Before we discuss what we believe is a very exciting announcement and a significant milestone for both MoonLake and Helix, we would like to make some important disclaimers. And I will ask our CFO to do those. [Slide 2] Matthia |
|
| October 4, 2021 |
Exhibit 2.1 BUSINESS COMBINATION AGREEMENT by and among HELIX ACQUISITION CORP., MOONLAKE IMMUNOTHERAPEUTICS AG, THE ML PARTIES SIGNATORY HERETO, HELIX HOLDINGS LLC and MATTHIAS BODENSTEDT, IN HIS CAPACITY AS THE ML PARTIES? REPRESENTATIVE HEREUNDER DATED AS OF OCTOBER 4, 2021 TABLE OF CONTENTS Article I CERTAIN DEFINITIONS 3 Section 1.1 Certain Definitions 3 Article II INVESTMENT AND PURCHASE AND |
|
| October 4, 2021 |
Form of Amended and Restated Registration Rights Agreement. Exhibit 10.5 FORM OF AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of , 202, is made and entered into by and among: (i) MoonLake Immunotherapeutics (formerly known as Helix Acquisition Corp.), a Cayman Islands exempted company (the ?Company?); (ii) Helix Holdings LLC, a Cayman Islands limited liability compan |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2021 Helix Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction (Commission File Number) (I.R. |
|
| October 4, 2021 |
Form of Amended and Restated Shareholders’ Agreement. Exhibit 10.2 FORM OF RESTATED AND AMENDED SHAREHOLDERS? AGREEMENT of [date] between 1. Helix Acquisition Corp. c/o Cormorant Asset Management LLP, 200 Clarendon Street, 52nd Floor Boston, MA 02116, United States (hereinafter ?Helix?) and 2. Biotechnology Value Fund, L.P. 44 Montgomery Street, 40th Floor, San Francisco, CA 94104, United States (hereinafter ?Series A Investor 1?) 3. Biotechnology Va |
|
| October 4, 2021 |
Press Release, dated October 4, 2021. Exhibit 99.1 MoonLake ImmunotheraPeutics AG and Helix Acquisition Corp. Announce BUSINESS COMBINATION Agreement to Create PUBLICLY LISTED BIOTECHNOLOGY COMPANY ADVANCing tri-specific nanobody? sonelokimab - Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp.?s trust account and a private investment in public entity (PIPE) financing - Leading in |
|
| October 4, 2021 |
Exhibit 99.2 1 ? 2021 | Confidential and Proprietary MoonLake Immunotherapeutics AG Proposed deal with Helix Acquisition Corp. STRICTLY CONFIDENTIAL September 2021 www.moonlaketx.com 2 Disclaimer (1/2) ? 2021 | Confidential and Proprietary | MoonLake Immunotherapeutics AG Important Information for Investors This confidential presentation (?Presentation?) is for informational purposes only and is b |
|
| October 4, 2021 |
Exhibit 10.4 amendment to sponsor letter This Amendment, dated as of October 4, 2021 (this ?Amendment?) to that certain letter agreement, dated October 19, 2020, by and among Helix Holdings LLC, a Cayman Islands limited liability company (the ?Sponsor?), Helix Acquisition Corp., a Cayman Islands exempted company (the ?Company?), each of the undersigned individuals, each of whom is a member of the |
|
| October 4, 2021 |
Exhibit 10.4 amendment to sponsor letter This Amendment, dated as of October 4, 2021 (this ?Amendment?) to that certain letter agreement, dated October 19, 2020, by and among Helix Holdings LLC, a Cayman Islands limited liability company (the ?Sponsor?), Helix Acquisition Corp., a Cayman Islands exempted company (the ?Company?), each of the undersigned individuals, each of whom is a member of the |
|
| October 4, 2021 |
Exhibit 2.1 BUSINESS COMBINATION AGREEMENT by and among HELIX ACQUISITION CORP., MOONLAKE IMMUNOTHERAPEUTICS AG, THE ML PARTIES SIGNATORY HERETO, HELIX HOLDINGS LLC and MATTHIAS BODENSTEDT, IN HIS CAPACITY AS THE ML PARTIES? REPRESENTATIVE HEREUNDER DATED AS OF OCTOBER 4, 2021 TABLE OF CONTENTS Article I CERTAIN DEFINITIONS 3 Section 1.1 Certain Definitions 3 Article II INVESTMENT AND PURCHASE AND |
|
| October 4, 2021 |
Form of Amended and Restated Registration Rights Agreement. Exhibit 10.5 FORM OF AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of , 202, is made and entered into by and among: (i) MoonLake Immunotherapeutics (formerly known as Helix Acquisition Corp.), a Cayman Islands exempted company (the ?Company?); (ii) Helix Holdings LLC, a Cayman Islands limited liability compan |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 HELIX ACQUISI |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 HELIX ACQUIS |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 001-39630 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2021 (April 27, 2021) HELIX ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 001-39630 N/A (State or other jurisdiction of incorporation) |
|
| March 31, 2021 |
Exhibit 4.5 DESCRIPTION OF SECURITIES The following description of our Class A ordinary shares and Class B ordinary shares is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our amended and restated memorandum and articles of association, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this E |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39630 HELIX ACQUISITION CORP. (E |
|
| February 24, 2021 |
Merger Prospectus - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 HELIX TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-55722 81-4046024 (State or other jurisdiction of incorporation) (Commission |
|
| February 24, 2021 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 HELIX TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-55722 81-4046024 (State or other jurisdiction of incorporation) (Commission |
